Order Entry
United States
ContactUsLinkComponent
ALS (Acid Labile Subunit) ELISA, Eagle Biosciences
ALS (Acid Labile Subunit) ELISA, Eagle Biosciences
  102994-312
 :  
ALS (Acid Labile Subunit) ELISA, Eagle Biosciences
  102994-312
 :  E35
 :  
Restricted Products: To process your orders without delay, please provide the required business documentation to purchase this product.

To order chemicals, medical devices, or other restricted products please provide ID that includes your business name & shipping address via email [email protected] or fax 484.881.5997 referencing your VWR account number. Acceptable forms of ID are:

  • • State issued document with your organization's Federal Tax ID Number
  • • State issued document with your organization's Resale Tax ID Number
  • • City or County issued Business License
  • • State Department of Health Services License
  • • Any other ID issued by the State that includes the business name & address

* ATTN: California Customers may require additional documentation as part of the CA Health & Safety Code. Products that fall under this regulation will be placed on a mandatory 21-day hold after documentation is received. Avantor will not lift restrictions for residential shipping addresses.

 

  • Host:
  • Primary antibody reactivity:
  • Target protein:
    ALS
  • Description:
    ALS (Acid Labile Subunit) ELISA
  • Size:
    1 kit
  • Environmentally Preferable:
  • Cat. No.:
    102994-312
  • Supplier no.:
    E35

 

 

ALS ELISA is suited for the measuring ALS in human serum or EDTA-/heparin-/citrate plasma.

  • Dynamic Range: 1.5 - 40 mU/ml
  • Sensitivity: 0.2 mU/ml
  • Incubation: 3 hours

The acid-labile Subunit, is a synthezised as propeptide of 605 amino acids. The signal peptide, necessary for ALS secretion (AA 1-27) cleaved off enduring the transport process (Swiss-Prot P35858 Version 82). The mature protein consists of 578 amino acids and contains about 20 leucin rich sequence repeats. Beside the leucin-rich repeats several potential N-linked glycosylation sides have been described. Miller BS et al. were able to demonstrate that incomplete glycolsylation of IGFs, ALS and IGFBP-3 results in a decreased serum concentration of these proteins. Oral mannose therapy resulted in a partial normalization of the glycosylation pattern and went along with improved growth [8]. Mutations in or the complete knock out of the ALS gene result in IGF / IGFBP-3 deficiency and therewith in disturbation of growth [9,10]. Beside growth also other Endocrinology axes may be involved. In primary ALS deficiency hyperinsulinemia could be observed [11, 12]. Further, the ALS-IGF-IGFBP-system seems to be of relevance in coronary disease [13].